Navigation Links
Mirati Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/12/2013

y involve numerous risks and uncertainties, known and unknown, many of which are beyond Mirati's control. Such statements can usually be identified by the use of words such as "may", "would", "believe", "intend", "plan", "anticipate", "estimate" and other similar terminology, or state that certain actions, events or results "may" or "would" be taken, occur or be achieved. Forward-looking statements in this release include, but are not limited to, statements regarding the potential for accelerated approval path for MGCD265, ability to secure a partner for the mocetinostat program, and the ability to obtain an SPA from the FDA.

Whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks include those inherent in drug development, whether Mirati will be able to obtain financing when needed or on favorable terms, and other risks described in Mirati's filings with the Securities and Exchange Commission. In evaluating any forward-looking statements in this release, Mirati cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Mirati does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.

 Mirati Therapeutics, Inc.Consolidated Statements of Operations and Comprehensive Loss(In thousands except for share and per share amounts)

(Unaudited)Three months ended September 30,Nine months ended September 30,2013201220132012ExpensesResearch and development, net$

5,492$

4,249$

15,477$

10,105General and administrative3,7101,7178,6164,019Total opera
'/>"/>

SOURCE Mirati Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Mirati Therapeutics Prices Public Offering Of Common Stock
2. Sorrento Therapeutics Adopts Stockholder Rights Plan
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
5. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
6. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
7. Echo Therapeutics Announces Third Quarter 2013 Financial Results
8. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
9. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
10. PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics
11. PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... Canada, Key Trends and Opportunities to 2017 ... Synopsis The report provides in ... the Canadian personal accident and health insurance ...
(Date:8/20/2014)... , Aug. 20, 2014 Children ... can receive vaccinations to help prevent disease. The ... vaccination for all adults, but currently, many adults ... August is National Immunization Awareness Month, and the ... urging adults, especially those with lung disease, to ...
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that ... in its catalogue: Wireless Opportunities ... Zigbee, UWB WWAN, WMAN, WLAN and other ... Kalorama Information,s Wireless Opportunities in ... UWB WWAN, WMAN, WLAN and other technologies) ...
Breaking Medicine Technology:Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 3Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 4Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 5Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 7Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 8Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 9Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 10Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 11Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 12Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 13Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 14Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 15Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 16Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 17Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 18Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 19Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 20Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 21Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 22Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 23American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12
... , , , , ... Aug. 17 The US Food and Drug Administration (FDA) has approved ... sclerosis (MS) medicines from Novartis to help patients manage this devastating disease. ... for the treatment of relapsing forms of MS to reduce the frequency ...
... WA and VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... the first patient has been dosed in an open ... administered directly into the bladder in patients with bladder ... 1 trial of OGX-427 administered systemically in patients with ...
Cached Medicine Technology:US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 2US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 3US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 5US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 6US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 7OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 2OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 3OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 4
(Date:8/20/2014)... By Dennis Thompson ... -- A new experimental drug has saved a group of ... of Ebola virus that kills up to 90 percent of ... monkeys infected with lethal doses of Marburg virus, even when ... study published Aug. 20 in the journal Science Translational ...
(Date:8/20/2014)... discovered that the immune system is defective in people suffering ... sufferers have ongoing issues with pain. , The research ... also help to explain why some painkillers may not offer ... up to 10% of the community. There are different ... pain, which often has the greatest impact on sufferers, quality ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 Hundreds ... on behalf of women who were allegedly injured due ... forward in New Jersey’s Bergen County Superior Court, Bernstein ... issued on August 15, 2014, the Court has established ... for Mirena lawsuits that are part of the proceeding’s ...
(Date:8/20/2014)... 2014 (HealthDay News) -- Loss of brain cells that ... many seniors have trouble falling and staying asleep, a ... can be especially severe and often results in nighttime ... investigators analyzed data from the Rush Memory and Aging ... age 65 and are being followed until death, at ...
(Date:8/20/2014)... By Kathleen Doheny ... -- Breast reconstruction after a mastectomy has long been an ... percent of women choose it. "The most common reasons ... important, they weren,t interested in more surgery or they were ... Morrow, chief of breast surgery at Memorial Sloan Kettering Cancer ...
Breaking Medicine News(10 mins):Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:Pain treatments less effective for those with irritable bowel 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3
... , FRIDAY, Oct. 29 (HealthDay News) -- ... serious and chronic bouts of constipation, according to experts. ... consumption of water may be contributing to the problem, ... reported seeing a 30 percent rise in the number ...
... disease is being investigated in research led at the ... Trypanosomiasis, also known as sleeping sickness, affects between 50,000 ... is transmitted through the bite of the tsetse fly ... fever, headaches and disturbed sleep patterns. Without treatment, ...
... kidney failure patients in the United States are twice as likely ... although the likelihood is still low, a new studyfinds. About ... and 48 percent of them are 60 or older. The ... of the American Society of Nephrology , included kidney failure patients, ...
... GABLES, FL (October 28, 2010)To help unravel the mysteries ... in robotics, University of Miami (UM) developmental psychologists and ... Diego (UC San Diego) are studying infant-mother interactions and ... capable of learning social skills. The first phase ...
... from Mount Sinai School of Medicine have identified a ... to DNA during embryonic development and may function to ... modified by a small molecule called a phosphate, it ... signals during development. This discovery identifies a new diagnostic ...
... Oct. 28 (HealthDay News) -- The rate of new cases ... diabetes fell 35 percent between 1996 and 2007, a new ... disease, also known as end-stage renal disease (ESRD), that was ... 100,000 people during that time. The declining rates occurred in ...
Cached Medicine News:Health News:Chronic Constipation Appears to Be Increasing Among Kids 2Health News:UM researchers are studying child-mother interactions to design robots with social skills 2Health News:Newly discovered regulatory mechanism essential for embryo development and may contribute to cancer 2Health News:Drop Seen in Rate of End-Stage Kidney Disease in Diabetics 2
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Micro emulsifying needles, 18G....
Micro 2000, micro scissors micro 2000 supercut....
Medicine Products: